2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Upfront ASCT + RVd improves PFS in NDMM

Roshini Claire Anthony, 20220716110001

Upfront autologous stem cell transplantation (ASCT) plus lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), results of the phase III DETERMINATION trial showed.

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

Roshini Claire Anthony, 20220714180001

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

Panitumumab + mFOLFOX6 ups OS in 1L left-sided RAS wild-type mCRC in Japanese trial

Christina Lau, 20220714085821

Panitumumab plus modified FOLFOX6 (mFOLFOX6; fluorouracil, leucovorin, and oxaliplatin) as first-line therapy significantly improves overall survival (OS) vs bevacizumab plus mFOLFOX6 in patients with left-sided RAS wild-type (wt) metastatic colorectal cancer (mCRC), results of the Japanese PARADIGM trial have shown.

Can very low-risk breast cancer patients be spared from postop radiotherapy?

Audrey Abella, 20220712100000

Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.

Adagrasib promising in KRASG12C-mutated NSCLC

Elvira Manzano, 20220705000000

The KRAS^G12C inhibitor adagrasib shows durable clinical benefit, without new safety signals, in pretreated patients with advanced non–small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation in the KRYSTAL-1 trial.

Novel targeted therapy shows better response than chemo in BRAF V600-mutant paediatric LGG

Elaine Soliven, 20220705000000

The combination of two targeted therapies, dabrafenib and trametinib, significantly improves the overall response rate (ORR) in paediatric patients with low-grade glioma (LGG) with BRAF V600 mutations compared with the combination of standard chemotherapy drugs, according to a study presented at ASCO 2022.

Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma

Roshini Claire Anthony, 20220630180001

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

Brentuximab vedotin + chemo ups EFS in high-risk paediatric Hodgkin lymphoma

Elaine Soliven, 20220628000000

The combination of brentuximab vedotin (Bv) and chemotherapy was superior to a standard paediatric dose-intensive chemotherapy regimen in boosting event-free survival (EFS) in paediatric patients with high-risk Hodgkin lymphoma (HL), according to the phase III AHOD1331* trial presented at ASCO 2022.

Dostarlimab in rectal cancer: are we inching towards a cure?

Audrey Abella, 20220622100000

In what has been dubbed as ‘a small but mighty study’ at ASCO 2022, a phase II trial spearheaded by investigators from Memorial Sloan Kettering Cancer Center in New York, US heralded the remarkable efficacy and safety of the monoclonal antibody dostarlimab for the treatment of locally advanced mismatch repair-deficient (dMMR) rectal cancer.